{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:52:51Z","timestamp":1778867571188,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s13402-018-0400-x","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T04:00:42Z","timestamp":1536033642000},"page":"677-686","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["In silico screening for ER\u03b1 down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ER\u03b1-expressing breast cancer cells"],"prefix":"10.1007","volume":"41","author":[{"given":"Claudia","family":"Busonero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Leone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4651-2509","authenticated-orcid":false,"given":"Filippo","family":"Acconcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"400_CR1","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrclinonc.2015.169","volume":"12","author":"F Bertolini","year":"2015","unstructured":"F. Bertolini, V.P. Sukhatme, G. Bouche, Nature reviews. Clin. Oncol. 12, 732\u2013742 (2015). \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2015.169","journal-title":"Clin. Oncol."},{"key":"400_CR2","doi-asserted-by":"crossref","unstructured":"F. Lumachi, G. Luisetto, S.M. Basso, U. Basso, A. Brunello and V. Camozzi, Curr Med Chem 18, 513\u2013522 (2011) doi: not available","DOI":"10.2174\/092986711794480177"},{"key":"400_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrc3093","volume":"11","author":"C Thomas","year":"2011","unstructured":"C. Thomas, J.A. Gustafsson, Nat. Rev. Cancer 11, 597\u2013608 (2011). \n                    https:\/\/doi.org\/10.1038\/nrc3093","journal-title":"Nat. Rev. Cancer"},{"key":"400_CR4","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1093\/eurpub\/ckx134","volume":"27","author":"J Chauvin","year":"2017","unstructured":"J. Chauvin, M. Lomazzi, The digital technology revolution and its impact on the public\u2019s health. Eur. J. Pub. Health 27, 947 (2017). \n                    https:\/\/doi.org\/10.1093\/eurpub\/ckx134","journal-title":"Eur. J. Pub. Health"},{"key":"400_CR5","doi-asserted-by":"publisher","unstructured":"S.E. Clare, P.L. Shaw, \u201cBig Data\u201d for breast cancer: where to look and what you will find. NPJ Breast Cancer 2, (2016). \n                    https:\/\/doi.org\/10.1038\/npjbcancer.2016.31","DOI":"10.1038\/npjbcancer.2016.31"},{"key":"400_CR6","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3389\/fgene.2014.00342","volume":"5","author":"D Vidovic","year":"2014","unstructured":"D. Vidovic, A. Koleti, S.C. Schurer, Large-scale integration of small molecule-induced genome-wide transcriptional responses, Kinome-wide binding affinities and cell-growth inhibition profiles reveal global trends characterizing systems-level drug action. Front. Genet. 5, 342 (2014). \n                    https:\/\/doi.org\/10.3389\/fgene.2014.00342","journal-title":"Front. Genet."},{"key":"400_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s13402-017-0322-z","volume":"40","author":"C Busonero","year":"2017","unstructured":"C. Busonero, S. Leone, F. Acconcia, Emetine induces estrogen receptor alpha degradation and prevents 17\u03b2-estradiol-induced breast cancer cell proliferation. Cell. Oncol. 40, 299\u2013301 (2017). \n                    https:\/\/doi.org\/10.1007\/s13402-017-0322-z","journal-title":"Cell. Oncol."},{"key":"400_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.mce.2017.07.027","volume":"460","author":"C Busonero","year":"2018","unstructured":"C. Busonero, S. Leone, C. Klemm, F. Acconcia, A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17\u03b2-estradiol: ER\u03b1 signaling and cell proliferation in breast cancer cells. Mol. Cell. Endocrinol. 460, 229\u2013237 (2018). \n                    https:\/\/doi.org\/10.1016\/j.mce.2017.07.027","journal-title":"Mol. Cell. Endocrinol."},{"key":"400_CR9","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1002\/jcp.26251","volume":"233","author":"S Leone","year":"2017","unstructured":"S. Leone, C. Busonero, F. Acconcia, A high throughput method to study the physiology of E2:ER\u03b1 signaling in breast cancer cells. J. Cell. Physiol. 233, 3713\u20133722 (2017). \n                    https:\/\/doi.org\/10.1002\/jcp.26251","journal-title":"J. Cell. Physiol."},{"key":"400_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.mce.2016.10.033","volume":"457","author":"F Acconcia","year":"2016","unstructured":"F. Acconcia, M. Fiocchetti, M. Marino, Xenoestrogen regulation of ER\u03b1\/ER\u03b2 balance in hormone-associated cancers. Mol. Cell. Endocrinol. 457, 3\u201312 (2016). \n                    https:\/\/doi.org\/10.1016\/j.mce.2016.10.033","journal-title":"Mol. Cell. Endocrinol."},{"key":"400_CR11","first-page":"6075","volume":"50","author":"HD Soule","year":"1990","unstructured":"H.D. Soule, T.M. Maloney, S.R. Wolman, W.D. Peterson Jr., R. Brenz, C.M. McGrath, J. Russo, R.J. Pauley, R.F. Jones, S.C. Brooks, Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 50, 6075\u20136086 (1990)","journal-title":"Cancer Res."},{"key":"400_CR12","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1210\/en.2002-220620","volume":"144","author":"JM Knowlden","year":"2003","unstructured":"J.M. Knowlden, I.R. Hutcheson, H.E. Jones, T. Madden, J.M. Gee, M.E. Harper, D. Barrow, A.E. Wakeling, R.I. Nicholson, Elevated Levels of Epidermal Growth Factor Receptor\/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells. Endocrinology 144, 1032\u20131044 (2003). \n                    https:\/\/doi.org\/10.1210\/en.2002-220620","journal-title":"Endocrinology"},{"key":"400_CR13","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/onc.2016.382","volume":"36","author":"A Harrod","year":"2017","unstructured":"A. Harrod, J. Fulton, V.T.M. Nguyen, M. Periyasamy, L. Ramos-Garcia, C.F. Lai, G. Metodieva, A. de Giorgio, R.L. Williams, D.B. Santos, P.J. Gomez, M.L. Lin, M.V. Metodiev, J. Stebbing, L. Castellano, L. Magnani, R.C. Coombes, L. Buluwela, S. Ali, Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene 36, 2286\u20132296 (2017). \n                    https:\/\/doi.org\/10.1038\/onc.2016.382","journal-title":"Oncogene"},{"key":"400_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12920-016-0212-7","volume":"9","author":"HR Chen","year":"2016","unstructured":"H.R. Chen, D.H. Sherr, Z. Hu, C. DeLisi, A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer. BMC Med. Genet. 9, 51 (2016). \n                    https:\/\/doi.org\/10.1186\/s12920-016-0212-7","journal-title":"BMC Med. Genet."},{"key":"400_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.compbiomed.2014.12.019","volume":"61","author":"L Zhu","year":"2015","unstructured":"L. Zhu, J. Liu, Integration of a prognostic gene module with a drug sensitivity module to identify drugs that could be repurposed for breast cancer therapy. Comput. Biol. Med. 61, 163\u2013171 (2015). \n                    https:\/\/doi.org\/10.1016\/j.compbiomed.2014.12.019","journal-title":"Comput. Biol. Med."},{"key":"400_CR16","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jsbmb.2009.01.004","volume":"113","author":"AM Marchionatti","year":"2009","unstructured":"A.M. Marchionatti, G. Picotto, C.J. Narvaez, J. Welsh, N.G. Tolosa de Talamoni, Antiproliferative action of menadione and 1,25(OH)2D3 on breast cancer cells. J. Steroid Biochem. Mol. Biol. 113, 227\u2013232 (2009). \n                    https:\/\/doi.org\/10.1016\/j.jsbmb.2009.01.004","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"400_CR17","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/bcr2120","volume":"10","author":"C Yau","year":"2008","unstructured":"C. Yau, C.C. Benz, Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers. Breast Cancer Research: BCR 10, R61 (2008). \n                    https:\/\/doi.org\/10.1186\/bcr2120","journal-title":"Breast Cancer Research: BCR"},{"key":"400_CR18","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1158\/0008-5472.CAN-17-1265","volume":"77","author":"Y Zhao","year":"2017","unstructured":"Y. Zhao, M.J. Laws, V.S. Guillen, Y. Ziegler, J. Min, A. Sharma, S.H. Kim, D. Chu, B.H. Park, S. Oesterreich, C. Mao, D.J. Shapiro, K.W. Nettles, J.A. Katzenellenbogen, B.S. Katzenellenbogen, Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors. Cancer Res. 77, 5602\u20135613 (2017). \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1265","journal-title":"Cancer Res."},{"key":"400_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13058-017-0851-4","volume":"19","author":"A Bahreini","year":"2017","unstructured":"A. Bahreini, Z. Li, P. Wang, K.M. Levine, N. Tasdemir, L. Cao, H.M. Weir, S.L. Puhalla, N.E. Davidson, A.M. Stern, D. Chu, B.H. Park, A.V. Lee, S. Oesterreich, Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Research: BCR 19, 60 (2017). \n                    https:\/\/doi.org\/10.1186\/s13058-017-0851-4","journal-title":"Breast Cancer Research: BCR"},{"key":"400_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1210\/en.2017-00693","volume":"159","author":"Z Li","year":"2017","unstructured":"Z. Li, K.M. Levine, A. Bahreini, P. Wang, D. Chu, B.H. Park, S. Oesterreich, A.V. Lee, Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells. Endocrinology 159, 285\u2013296 (2017). \n                    https:\/\/doi.org\/10.1210\/en.2017-00693","journal-title":"Endocrinology"},{"key":"400_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fonc.2017.00026","volume":"7","author":"T Reinert","year":"2017","unstructured":"T. Reinert, E.D. Saad, C.H. Barrios, J. Bines, Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. Front. Oncol. 7, 26 (2017). \n                    https:\/\/doi.org\/10.3389\/fonc.2017.00026","journal-title":"Front. Oncol."},{"key":"400_CR22","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jcp.25218","volume":"231","author":"P Totta","year":"2015","unstructured":"P. Totta, F. Gionfra, C. Busonero, F. Acconcia, Modulation of 17\u03b2-estradiol signaling on cellular proliferation by Caveolin-2. J. Cell. Physiol. 231, 1219\u20131225 (2015). \n                    https:\/\/doi.org\/10.1002\/jcp.25218","journal-title":"J. Cell. Physiol."},{"issue":"25","key":"400_CR23","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","volume":"34","author":"Hope S. Rugo","year":"2016","unstructured":"H.S. Rugo, R.B. Rumble, E. Macrae, D.L. Barton, H.K. Connolly, M.N. Dickler, L. Fallowfield, B. Fowble, J.N. Ingle, M. Jahanzeb, S.R. Johnston, L.A. Korde, J.L. Khatcheressian, R.S. Mehta, H.B. Muss and H.J. Burstein, Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline J. Clin. Oncol. 34, 3069\u20133103 (2016). \n                    https:\/\/doi.org\/10.1200\/JCO.2016.67.1487","journal-title":"Journal of Clinical Oncology"},{"key":"400_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1158\/2159-8290.CD-15-1523","volume":"7","author":"W Toy","year":"2017","unstructured":"W. Toy, H. Weir, P. Razavi, M. Lawson, A.U. Goeppert, A.M. Mazzola, A. Smith, J. Wilson, C. Morrow, W.L. Wong, E. De Stanchina, K.E. Carlson, T.S. Martin, S. Uddin, Z. Li, S. Fanning, J.A. Katzenellenbogen, G. Greene, J. Baselga, S. Chandarlapaty, Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discovery 7, 277\u2013287 (2017). \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1523","journal-title":"Cancer Discovery"},{"key":"400_CR25","doi-asserted-by":"publisher","unstructured":"J.D. Joseph, B. Darimont, W. Zhou, A. Arrazate, A. Young, E. Ingalla, K. Walter, R.A. Blake, J. Nonomiya, Z. Guan, L. Kategaya, S.P. Govek, A.G. Lai, M. Kahraman, D. Brigham, J. Sensintaffar, N. Lu, G. Shao, J. Qian, K. Grillot, M. Moon, R. Prudente, E. Bischoff, K.J. Lee, C. Bonnefous, K.L. Douglas, J.D. Julien, J.Y. Nagasawa, A. Aparicio, J. Kaufman, B. Haley, J.M. Giltnane, I.E. Wertz, M.R. Lackner, M.A. Nannini, D. Sampath, L. Schwarz, H.C. Manning, M.N. Tantawy, C.L. Arteaga, R.A. Heyman, P.J. Rix, L. Friedman, N.D. Smith, C. Metcalfe and J.H. Hager, The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. eLife 5, (2016). \n                    https:\/\/doi.org\/10.7554\/eLife.15828","DOI":"10.7554\/eLife.15828"},{"key":"400_CR26","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1038\/s41467-017-01864-y","volume":"8","author":"LA Martin","year":"2017","unstructured":"L.A. Martin, R. Ribas, N. Simigdala, E. Schuster, S. Pancholi, T. Tenev, P. Gellert, L. Buluwela, A. Harrod, A. Thornhill, J. Nikitorowicz-Buniak, A. Bhamra, M.O. Turgeon, G. Poulogiannis, Q. Gao, V. Martins, M. Hills, I. Garcia-Murillas, C. Fribbens, N. Patani, Z. Li, M.J. Sikora, N. Turner, W. Zwart, S. Oesterreich, J. Carroll, S. Ali, M. Dowsett, Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. Nat. Commun. 8, 1865 (2017). \n                    https:\/\/doi.org\/10.1038\/s41467-017-01864-y","journal-title":"Nat. Commun."},{"key":"400_CR27","doi-asserted-by":"publisher","first-page":"34753","DOI":"10.1038\/srep34753","volume":"6","author":"C Mao","year":"2016","unstructured":"C. Mao, M. Livezey, J.E. Kim, D.J. Shapiro, Antiestrogen resistant cell lines expressing estrogen receptor \u03b1 mutations upregulate the unfolded protein response and are Killed by BHPI. Sci. Rep. 6, 34753 (2016). \n                    https:\/\/doi.org\/10.1038\/srep34753","journal-title":"Sci. Rep."},{"key":"400_CR28","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1021\/jm400045y","volume":"56","author":"X Wan","year":"2013","unstructured":"X. Wan, W. Zhang, L. Li, Y. Xie, W. Li, N. Huang, A new target for an old drug: Identifying mitoxantrone as a nanomolar inhibitor of PIM1 kinase via kinome-wide selectivity modeling. J. Med. Chem. 56, 2619\u20132629 (2013). \n                    https:\/\/doi.org\/10.1021\/jm400045y","journal-title":"J. Med. Chem."},{"key":"400_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.biopha.2017.11.012","volume":"97","author":"X Jiang","year":"2017","unstructured":"X. Jiang, Z. Chen, G. Shen, Y. Jiang, L. Wu, X. Li, G. Wang, T. Yin, Psychotropic agent thioridazine elicits potent in vitro and in vivo anti-melanoma effects. Biomed. Pharmacother. 97, 833\u2013837 (2017). \n                    https:\/\/doi.org\/10.1016\/j.biopha.2017.11.012","journal-title":"Biomed. Pharmacother."},{"key":"400_CR30","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"R. Jeselsohn, G. Buchwalter, C. De Angelis, M. Brown, R. Schiff, ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nature Rev. Clin. Oncol. 12, 573\u2013583 (2015). \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2015.117","journal-title":"Nature Rev. Clin. Oncol."},{"key":"400_CR31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nrc2713","volume":"9","author":"EA Musgrove","year":"2009","unstructured":"E.A. Musgrove, R.L. Sutherland, Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631\u2013643 (2009). \n                    https:\/\/doi.org\/10.1038\/nrc2713","journal-title":"Nat. Rev. Cancer"},{"key":"400_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ccell.2018.01.004","volume":"33","author":"R Jeselsohn","year":"2018","unstructured":"R. Jeselsohn, J.S. Bergholz, M. Pun, M. Cornwell, W. Liu, A. Nardone, T. Xiao, W. Li, X. Qiu, G. Buchwalter, A. Feiglin, K. Abell-Hart, T. Fei, P. Rao, H. Long, N. Kwiatkowski, T. Zhang, N. Gray, D. Melchers, R. Houtman, X.S. Liu, O. Cohen, N. Wagle, E.P. Winer, J. Zhao, M. Brown, Allele-specific chromatin recruitment and therapeutic vulnerabilities of ESR1 activating mutations. Cancer Cell 33, 173\u2013186 e175 (2018).\n                    https:\/\/doi.org\/10.1016\/j.ccell.2018.01.004","journal-title":"Cancer Cell"},{"key":"400_CR33","unstructured":"J.S. Strobl and V.A. Peterson, Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13.T. J. Pharmacol. Exp. Ther. 263, 186\u2013193 (1992)"},{"key":"400_CR34","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.canlet.2018.04.023","volume":"428","author":"L Gelsomino","year":"2018","unstructured":"L. Gelsomino, S. Panza, C. Giordano, I. Barone, G. Gu, E. Spina, S. Catalano, S. Fuqua, S. Ando, Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines. Cancer Lett. 428, 12\u201320 (2018). \n                    https:\/\/doi.org\/10.1016\/j.canlet.2018.04.023","journal-title":"Cancer Lett."},{"key":"400_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s13402-017-0324-x","volume":"40","author":"R Sharma","year":"2017","unstructured":"R. Sharma, R. Sharma, T.P. Khaket, C. Dutta, B. Chakraborty, T.K. Mukherjee, Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1. Cell. Oncol. 40, 199\u2013208 (2017). \n                    https:\/\/doi.org\/10.1007\/s13402-017-0324-x","journal-title":"Cell. Oncol."},{"key":"400_CR36","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13402-017-0330-z","volume":"40","author":"M Godbole","year":"2017","unstructured":"M. Godbole, K. Tiwary, R. Badwe, S. Gupta, A. Dutt, Progesterone suppresses the invasion and migration of breast cancer cells irrespective of their progesterone receptor status - a short report. Cell. Oncol. 40, 411\u2013417 (2017). \n                    https:\/\/doi.org\/10.1007\/s13402-017-0330-z","journal-title":"Cell. Oncol."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13402-018-0400-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-018-0400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-018-0400-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T19:16:44Z","timestamp":1567538204000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13402-018-0400-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["400"],"URL":"https:\/\/doi.org\/10.1007\/s13402-018-0400-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/325746","asserted-by":"object"}]},"ISSN":["2211-3428","2211-3436"],"issn-type":[{"value":"2211-3428","type":"print"},{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"assertion":[{"value":"9 August 2018","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}